Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2009 September;21(3) > Minerva Biotecnologica 2009 September;21(3):147-51

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA BIOTECNOLOGICA

A Journal on Biotechnology and Molecular Biology


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,25


eTOC

 

ORIGINAL ARTICLES  FREEfree


Minerva Biotecnologica 2009 September;21(3):147-51

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Protein carbonyl contents in cerebrospinal fluid and serum of patients affected by multiple sclerosis

Gangemi S. 1, Cristani M. 2, Morabito F. 3, Aguglia U. 4, Russo C. 5, Morabito P. 5, Minciullo P. L. 1, Tomaino A. 2, Cimino F. 2, Saija A. 2

1 School of Allergy and Clinical Immunology, Department of Human Pathology, University of Messina, Messina, Italy 2 School of Pharmacy, Department Farmaco-Biologico, University of Messina, Messina, Italy 3 Hematology Unit, Department of Medicine, Azienda Ospedaliera, Cosenza, Italy 4 Institute of Neurology, Magna Graecia University, Catanzaro, Italy 5 Neurologic Unit, Ospedali Riuniti, Reggio Calabria, Italy


FULL TEXT  


It is known that oxidative stress is involved in the pathogenesis of multiple sclerosis (MS), in particular, protein carbonylation. The aim of this study was to evaluate whether cerebrospinal fluid (CSF) carbonylated proteins could be used as a marker of cerebral oxidative activity in MS patients. The serum concentrations of malondialdehyde/hydroxynonenal, thiol groups and protein carbonyl groups were evaluated, together with the CSF levels of thiol groups and protein carbonyl groups in 33 MS patients and 19 patients with other inflammatory neurological diseases. Findings suggest that CSF carbonylated proteins might be used as a marker of cerebral oxidative activity in MS patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail